Last ¥2,109 JPY
Change Today -10.00 / -0.47%
Volume 1.7M
4543 On Other Exchanges
Symbol
Exchange
Munich
Tokyo
OTC US
As of 2:00 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

terumo corp (4543) Snapshot

Open
¥2,111
Previous Close
¥2,119
Day High
¥2,123
Day Low
¥2,096
52 Week High
05/23/13 - ¥2,915
52 Week Low
04/11/14 - ¥2,003
Market Cap
800.9B
Average Volume 10 Days
2.6M
EPS TTM
¥155.90
Shares Outstanding
379.8M
EX-Date
03/27/14
P/E TM
13.5x
Dividend
¥29.00
Dividend Yield
1.38%
Current Stock Chart for TERUMO CORP (4543)

Related News

No related news articles were found.

terumo corp (4543) Related Businessweek News

No Related Businessweek News Found

terumo corp (4543) Details

Terumo Corporation manufactures and sells medical products and equipment in Japan and internationally. The company operates through Cardiac and Vascular Business, Blood Management Business, and General Hospital Business segments. It offers general hospital devices and systems used for treatments at hospital bedsides and in the home, including nutrient solutions for total parenteral nutrition, safety intravenous catheters, infusion sets, infusion/syringe pumps, plastic prefilled syringes, oncology safety products and closed system solutions, blood glucose monitoring systems, needle for pen-injectors, calorie-dense liquid meals, CAPD systems, digital thermometers, stumbling-preventive socks, lancing devices for blood collection, upper arm blood pressure monitors, activity monitors, basal body thermometers, urine test strips, and support wear. It also offers products for vascular interventional treatment, including intra-vascular ultrasound systems, PTCA balloon and angiographic catheters, drug eluting stents, guidewires, introducer sheaths, endovascular coils, and peripheral stents. In addition, the company provides cardiovascular system products, such as heart-lung machines, oxygenators, platelet-rich plasma collectors/kits, artificial thoracic vascular grafts, porcine aortic valved conduits, and stent grafts. Further, it offers blood management products, including automated blood collection systems, automated blood component processing devices, blood bag systems, sterile tubing welders, and pathogen reduction technology systems; therapeutic apheresis systems; and cell expansion systems for biotech and cell processing. The company was formerly known as The Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was founded in 1921 and is headquartered in Tokyo, Japan.

18,893 Employees
Last Reported Date: 06/27/13
Founded in 1921

terumo corp (4543) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

terumo corp (4543) Key Developments

Biosensors Japan Co., Ltd. and Terumo Extend Licensing Agreements and Deepen Sales Collaboration for Nobori DES

Biosensors International Group, Ltd. announced an extension of their existing licensing agreements and an expansion of their sales collaboration in Japan, with regard to Terumo's Nobori® drug-eluting stent. Under the agreements, Terumo will continue to incorporate BioMatrixTM technology in the production, marketing and sales of the Nobori® drug-eluting stent in territories outside of Japan, excluding the United States, until December 2016. As per the original agreements, Terumo currently benefits from its existing rights in Japan to manufacture, market and sell Nobori®. By expanding the existing sales collaboration between Terumo and Biosensors Japan Co., Ltd., the Japanese subsidiary of Biosensors, the companies intend to bolster Japanese sales of Nobori® and increase its market share.

Arterial Remodeling Technologies Signs Structured Buyout Agreement with Terumo Corporation

Arterial Remodeling Technologies ('ART') announced that it has signed a structured buyout agreement with Terumo Corporation. Under the agreement, ART and Terumo Corporation will collaborate in the development of a drug eluting bioresorbable scaffold or stent, intended for use in the treatment of coronary artery disease. ART Security Holders will retain full ownership of the ART bioresorbable scaffold technology for all other indications. Terumo Corporation will make staged R&D investments in ART and ART has granted an exclusive option to Terumo Corporation to purchase ART at any time prior to the initiation of clinical trials. ART's advanced bioresorbable scaffold is designed to provide a transient effective scaffold that dismantles and relinquishes its primary mechanical scaffolding function after three months, which is commonly recognized by experts as the requisite length of time necessary to allow the healing process to stabilize the artery following trauma generated by angioplasty, and to avoid recoil and constrictive remodeling.

Terumo Corporation Announces Earnings Results for the Nine Months Ended December 31, 2013; Provides Earnings Guidance for the Fiscal Year Ending March 31, 2014

Terumo Corporation announced earnings results for the nine months ended December 31, 2013. For the nine months, the company has reported that net income was JPY 36.90 billion, or JPY 194.32 per share, compared to JPY 24.71 billion, or JPY 130.12 per share, for the same period ended December 31, 2012. Net sales for the nine months ended December 31, 2013 were JPY 345.26 billion, compared to JPY 295.75 billion for the same period ended December 31, 2012. Operating income for the nine months ended December 31, 2013 was JPY 48.25 billion, compared to JPY 42.63 billion for the same period ended December 31, 2012. Ordinary income for the nine months ended December 31, 2013 was JPY 49.92 billion, compared to JPY 40.45 billion for the same period ended December 31, 2012. The company provided earnings guidance for the fiscal year ending March 31, 2014. For the year ending March 31, 2014, the company expects net sales to be JPY 460 billion, and net income to be JPY 42 billion, or JPY 221.20 per share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4543:JP ¥2,109.00 JPY -10.00

4543 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CareFusion Corp $38.35 USD -0.30
Getinge AB kr181.80 SEK -1.80
Hospira Inc $43.00 USD -0.43
Nipro Corp ¥890.00 JPY +1.00
West Pharmaceutical Services Inc $43.03 USD 0.00
View Industry Companies
 

Industry Analysis

4543

Industry Average

Valuation 4543 Industry Range
Price/Earnings 14.0x
Price/Sales 1.8x
Price/Book 1.6x
Price/Cash Flow 12.0x
TEV/Sales 1.2x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TERUMO CORP, please visit www.terumo.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.